Tempus AI (TEM) traded lower today, down roughly 3% to about $51.46, as traders focused on fresh insider-transaction disclosures circulating in the market. A Form 4 posted to Tempus’ investor site shows sales by CEO and Chairman Eric Lefkofsky (transactions dated February 19–20, 2025), which can act as a near-term sentiment headwind even when sales are pre-planned or tax-related. (investors.tempus.com)

TEM has been prone to sharp swings as investors weigh high-growth AI/precision-medicine upside against ongoing cash-burn and headline risk. With the stock having rebounded into the low-$50s range in recent weeks, incremental signals of insider monetization can prompt profit-taking and tighten risk appetite across momentum holders.

Separately, company filings describe two class-action lawsuits filed February 12–13, 2026 in federal court in Illinois alleging violations of the Illinois Genetic Information Privacy Act and seeking class-action status; Tempus has said it believes the suits are without merit and intends to defend them. The same filing outlines ongoing litigation with Guardant related to patent claims and related disputes, reinforcing that TEM carries meaningful legal headline risk alongside its operating story. (investors.tempus.com)